Medicinova (MNOV) EBITDA Margin (2012 - 2026)

Medicinova (MNOV) posted quarterly EBITDA Margin of 2037.97% for Q4 2025, up 25.67% quarter-over-quarter from 2741.67% in Q3 2025.

Medicinova (MNOV) EBITDA Margin (2012 - 2026) Analysis & Trends

Medicinova (MNOV) has reported EBITDA Margin for 5 consecutive years, with 2037.97% the latest figure, recorded in Q4 2025.

In Q4 2025, EBITDA Margin changed N/A year-over-year to 2037.97%; the TTM figure through Dec 2025 stood at 3242.47% (changed N/A YoY), while the FY2025 annual figure was 3242.47%, changed N/A from the prior year.
EBITDA Margin grew to 2037.97% in Q4 2025 per MNOV's latest filing, from 2741.67% in the prior quarter.
Across five years, EBITDA Margin topped out at 5.04% in Q1 2021 and bottomed at 9605.17% in Q3 2021.
Historically, EBITDA Margin has averaged 2864.07% across 3 years, with a median of 2358.93% in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Medicinova	66.94 Mn	66.94 Mn	317,759.00	-554.31%

Download Data